ENTITY
Keymed Biosciences

Keymed Biosciences (2162 HK)

104
Analysis
Health Care • China
Keymed Biosciences is a biotechnology company focused on the in-house discovery and development of innovative biological therapies for autoimmune diseases and oncology. Their pipeline includes over 50 programs, with key products like Kangyueda® (Stapokibart, CM310) for atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. The company was founded in 2016 and is headquartered in Chengdu, China.
more
•18 Aug 2025 19:01

Quiddity Leaderboard Hang Seng Biotech Sep25: Announcement Soon; MANY DELs Likely!

There are 20 deletions expected due to drastic changes to the index selection methodology. These names have underperformed the index in the last...

Share
•01 Jul 2025 13:30

Hong Kong Connect Flows (June): Inflows Accelerated, Xiaomi/Tencent Profit Taking Continued

We analyzed the Hong Kong Connect Scheme for June and highlighted flows for Tencent (700 HK), Meituan (3690 HK), CCB (939 HK), Xiaomi (1810 HK),...

Logo
664 Views
Share
•25 Jun 2025 08:55

Pre-IPO Cloudbreak Pharma (PHIP Updates) - Some Points Worth the Attention

​Low diagnosis/treatment rate for pterygium may impact willingness to pay for CBT-001. Commercialization outlook is highly uncertain due to...

Logo
692 Views
Share
bullish•Kioxia Holdings
•16 Jun 2025 08:08

ECM Weekly (16 June 2025) - Haitian, Sanhua, Kitazato, Primo, Kioxia, Xtalpi, Horizon, Keymed, Wuxi

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
655 Views
Share
bullish•Wuxi Biologics
•15 Jun 2025 09:34

China Healthcare Weekly (Jun.15) - Outlook of GLP-1 Market, WuXi Bio’s Placement, Keymed's Placement

GLP-1 market is approaching ceiling. WuXi Bio’s Placing price of HK$26.51-26.88 is expensive based on our forecast. Keymed's reasonable valuation...

Logo
628 Views
Share
x